Get started
Author

Kamesh R. Kuchimanchi

Observed names: Kamesh Kuchimanchi, Kamesh R Kuchimanchi
ORCID: 0009-0003-3288-3450
Observed ORCID: 0009-0003-3288-3450
OpenAlex ID: A5111551744
An antibody to IP-10 is a potent antagonist of cell migrationin vitroandin vivoand does not affect disease in several animal models of inflammation
2009 · Fergus R. Byrne, Aaron Winters, et al. · Autoimmunity · 20
Inducing a change in the pharmacokinetics and biodistribution of poly-l-lysine in rats by complexation with heparin
2003 · Thomas P Johnston, Kamesh R Kuchimanchi, et al. · Journal of Pharmacy and Pharmacology · 9
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024 · R. Leo Sakemura, Mehrdad Hefazi, et al.
Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).
2021 · Emily Brooks, Claudia Lebedinsky, et al. · Journal of Clinical Oncology
Works count: 12
Citation count: 29
H-index: 2
I10-index: 1
Year
Topic
Type